An interventional study of Intravenous Infusion and Intravenous Infusion in Pancreatectomy; Hyperglycemia, sponsored by University Hospital, Gentofte, Copenhagen. Completed at 1 site in Denmark. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-09-09.
Sponsored by University Hospital, Gentofte, Copenhagen · Not applicable, Interventional, and Basic science
The two gut-derived hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) are secreted from intestinal cells in relation to a meal and increase insulin secretion from the pancreas. The hormones also exert effects outside the pancreas, but especially for GIP, these are poorly investigated. Because of this, only GLP-1 based drugs (GLP-1 receptor agonists) are on the market for the treatment of type 2 diabetes and obesity. Nonetheless, a new drug is in clinical development: a combined GIP-GLP-1-receptor agonist (tirzepatide), which has shown better results than GLP-1 alone. The mechanism behind these impressive effects are unknown and in this study, the investigators will look into the exptrapancreatic effects of GIP and GLP-1, separate and combined and thus elucidate the mechanisms of action of this new drug class.
699 studies on the registry are indexed under Hyperglycemia; 105 are open to participants now.
This study's enrollment of 12 is below the median of 46 across 521 interventional studies indexed under Hyperglycemia.
Browse Hyperglycemia studies →University Hospital, Gentofte, Copenhagen is the lead sponsor of 154 studies on the registry; 9 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Intravenous infusion of glucose-dependent insulinotropic polypeptide
Other: Intravenous Infusion
Intravenous infusion of glucagon-like peptide 1
Other: Intravenous Infusion
Intravenous infusion of glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1
Other: Intravenous Infusion
Intravenous infusion of saline
Other: Intravenous Infusion
Glucose-dependent Insulinotropic Polypeptide
Glucagon-Like Peptide 1
Glucose-dependent Insulinotropic Polypeptide and Glucagon-Like Peptide 1
Saline
Plasma glucose
Changes in plasma levels of glucose between interventions assessed through frequently blood sampling during the experimental days
Time frame: Up to two months
Plasma glucagon
Changes in plasma levels of glucagon (gut-derived) between interventions assessed through frequently blood sampling during the experimental days
Time frame: Up to two months
Plasma Insulin/C-peptide
Changes in plasma levels of insulin/C-peptide between interventions assessed through frequently blood sampling during the experimental days
Time frame: Up to two months
Plasma triglycerides
Changes in plasma triglycerides between interventions assessed through frequently blood sampling during the experimental days
Time frame: Up to two months
Plasma CTX
Changes in CTX between interventions assessed through frequently blood sampling during the experimental days
Time frame: Up to two months
Plasma PINP
Changes in plasma PINP between interventions assessed through frequently blood sampling during the experimental days
Time frame: Up to two months
Plan to share: Undecided
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Gentofte, Copenhagen